BIOGEN APPOINTS HANS-PETER HASLER EXECUTIVE VICE PRESIDENT, COMMERCIAL OPERATIONS

Biogen, Inc. (NASDAQ/BGEN) today announced that Hans-Peter Hasler has been appointed Executive Vice President, Commercial Operations. Mr. Hasler reports to James C. Mullen, President and Chief Executive Officer.

Mr. Hasler joins Biogen from Wyeth-Ayerst Pharmaceuticals, a subsidiary of American Home Products (AHP) where he worked for eight years, serving since 1998 as Senior Vice President, Head of Global Strategic Marketing, corporate headquarters in St. David’s, Pennsylvania. Mr. Hasler also was a member of the Wyeth/AHP Executive Committee and was chair of the Commercial Council. From 1993-1998, Mr. Hasler served in senior management capacities including Managing Director, Wyeth Group, Germany and General Manager AHP/Wyeth in Switzerland and Central Eastern Europe with head offices in Vienna, Austria. Prior to joining Wyeth-Ayerst, Mr. Hasler was Head of Pharma Division at Abbott AG, Zug, Switzerland. Mr. Hasler graduated with a Federal Commercial Diploma from the Central Authority of the Canton of Bern in Switzerland and in 1993 earned a Marketing Manager Certificate from the Swiss Institute of Business and Economics (SIB), Zurich, Switzerland.

Mr. Mullen said, “We are very excited to have Hans-Peter Hasler join our senior management team in this newly created position. He brings to Biogen a record of accomplishment in a diverse, international pharmaceutical environment. Hans-Peter has demonstrated the critical
operating and strategic skills in building and leading an organization across multi-functional, multi-cultural teams, which we believe, will accelerate Biogen’s global commercial growth well into the future.”

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from international sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.biogen.com.